shutterstock_246073315.jpg
shutterstock_373528693_small.jpg
shutterstock_317504351.jpg
shutterstock_246073315.jpg
shutterstock_246073315.jpg

Overview


Novel TRPV1 Agonist Prodrugs for Pain

SCROLL DOWN

Overview


Novel TRPV1 Agonist Prodrugs for Pain

We are developing a portfolio of novel, non-opioid therapeutics that provide long-lasting pain relief after a single local administration.

shutterstock_373528693_small.jpg

The Problem


The Problem

 

The Problem


The Problem

 

Current Postsurgical Treatment Options Fall Short

THERE IS NO "GOOD" WAY TO PROVIDE CONTINUOUS, EFFECTIVE PAIN RELIEF BEYOND THE FIRST 18-24 HOURS AFTER SURGERY.

  • Treating pain systemically with opioids provides relief but dramatically increases costs and morbidity

  • Treating pain at its source with local anesthetic is effective, but limited by its short duration of action

  • Treating pain with regional blocks is highly effective, but duration is less than 24 hours and relief is accompanied by muscle weakness and sensory numbness


Despite Advances In Cancer Treatment, Cancer Pain Continues To Be A Problem With A Heavy Reliance On Opioids

lung_cancer.png
  • Pain is the most feared symptom with cancer (Jain 2015)

  • Overall pain prevalence is 33% (more than 75% with advanced disease) (Paice 2011)

  • Severe pain prevalence is 5% (increases with advanced disease) and predicts near-term hospitalizations (Wagner-Johnston 2010)

  • Opioids, while the mainstay of treatment, are limited by side effects

  • Eventually, conservative treatments fail and require invasive approaches which are costly


There Are Few Durable, Effective and Safe Treatment Options For Moderate To Severe Osteoarthritis (OA) Pain

Body.png

THERE IS NO “GOOD” WAY TO PROVIDE DURABLE, EFFECTIVE RELIEF FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN.

  • NSAIDS only effective for mild-to-moderate and have significant safety issues (GI, Renal, CV)

  • Opioids provide limited, short-term relief but dramatically increase costs and morbidity

  • Intra-articular (IA) steroids are somewhat effective yet limited due to short duration of action

  • IA hyaluronic acid has limited differentiation from placebo in controlled clinical studies

shutterstock_317504351.jpg

Goal


Goal

 

Goal


Goal

 

Our goal is to drive the actualization of value-based health care by substantially reducing costs, improving outcomes and reducing complexity of care.

 
  • DECREASE OPIOID USE AND HARMFUL, COSTLY SEQUELAE

  • REDUCE DAILY PAIN AND INCREASE MOBILITY

  • REDUCE LOST-DAYS-OF-WORK AND HASTEN RETURN TO PRODUCTIVITY

  • REDUCE UNNECESSARY HOSPITAL COSTS INCLUDING: DECREASE TIME TO DISCHARGE AND DECREASE ER VISITS AND RE-ADMITTANCE

 
shutterstock_246073315.jpg

Attributes


Attributes of our prodrugs

Attributes


Attributes of our prodrugs

Reduced opioid consumption & opioid-related adverse events

NON-OPIOID


Targets pain at source with limited systemic exposure

SITE SPECIFIC


Single injection simplifies ongoing care

SIMPLE


Continuous and durable relief

LONG-LASTING


PAIN-SELECTIVE

Extended pain relief without numbness or weakness